跳至主要内容
临床试验/ITMCTR2000003812
ITMCTR2000003812尚未招募1 期

A randomized double-blind controlled clinical study of Qiangxin compound in the treatment of type 2 cardiorenal syndrome under the hierarchical management mode of Integrated Chinese and Western Medicine

Traditional Chinese Medicine Hospital of Shanghai0 个研究点开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 80(—)
性别
All

入选标准

  • Heart failure stage C, D, heart function II to III with mild to severe renal insufficiency.

排除标准

  • 1. Patients with renal insufficiency caused by non cardiac causes;
  • 2. Pregnant or lactating women, allergic constitution and allergic to a variety of drugs;
  • 3. Combined with severe liver insufficiency and endocrine system, hematopoietic system and other serious primary diseases;
  • 4. Those with mental disorder and unwilling to cooperate;
  • 5. The factors that can increase the mortality rate include cardiogenic shock, severe ventricular arrhythmia, complete atrioventricular block and obvious infection;
  • 6. Creatinine clearance rate < 15% of patients requiring dialysis;
  • 7. History of cardiac surgery.

研究者

发起方
Traditional Chinese Medicine Hospital of Shanghai

相似试验